Editorials

Does a Positive HLA-B27 Test Increase Your Risk of Mortality? N. Haroon ................................. 559

Analysis of Bone Samples from Patients with Spondyloarthritides — Identifying Causes of New Bone Formation in Axial Spondyloarthritis
H. Appel, J. Sieper ........................................... 561

Articles


Anti-carbamylated Protein Antibodies Are Present Prior to RA and Are Associated with its Future Diagnosis

Response to Tocilizumab in RA Is Not Influenced by the BMI of the Patient

A Qualitative Investigation of the Barriers to Help-seeking Among Members of the Public Presented with Symptoms of New-onset RA G. Simons, C.D. Maillen, K. Kumar, R.J. Stack, K. Raza ........................................... 585

Urinary Albumin Excretion Is Increased in Patients with RA and Associated with Arterial Stiffness
K. Becetti, A. Oesser, M. Ormseth, et al ..................... 593

Prediction of Clinical Response After 1 Year of Infliximab Therapy in RA Based on Disease Activity at 3 Months: Posthoc Analysis of the RISING Study

Intact Calibers of Retinal Vessels in Patients with SSc

Assessment of Risks of Pulmonary Infection During 12 Months Following Immunosuppressive Treatment for Active Connective Tissue Diseases: A Large-scale Prospective Cohort Study H. Yamazaki, R. Sakai, R. Koike, et al, for the PREVENT Study Group ............... 614

Objective Evaluation of Physical Functioning after TNF Inhibitory Therapy in Patients with Ankylosing Spondyloarthritis: A Selection of 3 Feasible Performance-based Tests
S.F. van Weely, J. Dekker, M.P. Steultjens, et al ............ 623

Bone Lineage Proteins in the Entheses of the Midfoot in Patients with Spondyloarthritis
C. Pacheco-Tena, R. Pérez-Tamayo, C. Pineda, et al ...... 630

Mortality in American Veterans with the HLA-B27 Gene

Disease Activity in Ankylosing Spondylitis and Associations to Markers of Vascular Pathology and Traditional Cardiovascular Disease Risk Factors: A Cross-sectional Study


2014 Update of CRA/SPARCC Treatment Recommendations for the Management of Spondyloarthritis. Part II: Specific Management Recommendations

Choosing Wisely: The Canadian Rheumatology Association’s List of 5 Items Physicians and Patients Should Question S.L. Chow, J.C. Thorne, M.J. Bell, et al, on behalf of the CRA Choosing Wisely Committee .................. 682

Leukemia and Myelodysplastic Syndrome in Granulomatosis with Polyangiitis: Subtypes, Clinical Characteristics, and Outcome
A. Knight, K. Hjorton, C. Sundström, et al ................... 690

Variants of the IFI16 Gene Affecting the Levels of Expression of mRNA Are Associated with Susceptibility to Behçet Disease L. Ortiz-Fernández, J.R. García-Lozano, M.A. Montes-Cano, et al ............................... 695

The Cost of Research: A Survey of Participating Sites in a Nationwide Registry J.L. Tress, D.D. Sherry ......................... 702

Pediatric Rheumatology

Abatacept in the Treatment of Severe, Longstanding, and Refractory Uveitis Associated with JIA
C. Tappeiner, E. Misirocchi, B. Bodaghi, et al ............... 706

Macrophage Activation Syndrome in Patients with Systemic JIA under Treatment with Tocilizumab S. Yokota, Y. Itoh, T. Morio, N. Sumitomo, K. Daimaru, S. Minota ........... 712

Free online via JRheum Full Release option

Contents continued on page xxii
Images in Rheumatology

Osseous Sarcoid
E.W. Kwok, E.A. Yacyshyn .......................... 723

“Mutilans-type” Jaccoud Arthropathy
M.B. Santiago, V. Machicado, D.S. Ribeiro .......................... 725

Correspondence

Evaluation of Leptin with Atherosclerosis in RA
M. Agilli, F.N. Aydin, Y.G. Kurt, T. Cayci .......................... 727

Reply
P.H. Dessein, L. Tsang, A.G. Woodiwiss,
A. Solomon .................................................. 727

Letters

Monoclonal Antibodies, Systemic Lupus Erythematosus,
and Pregnancy: Insights from an Open-label Study
V.K. Sandhu, D.J. Wallace, M.H. Weisman .......................... 728

Inclusion Body Myositis in a Patient with RNA Polymerase
III Antibody-positive SSc
S. Vemulapalli, L.R. Sharer, V.M. Hsu .......................... 730

Meetings in Rheumatology .............................................. s